Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023

DelveInsight’s, “Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023” report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic Obstructive Pulmonary Disease: Understanding

Chronic Obstructive Pulmonary Disease: Overview

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Also, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines a COPD exacerbation as an event in the natural course of the disease that is characterized by a change in the patient’s baseline dyspnea, cough, and sputum that is beyond normal day-to-day variations, is acute in onset, and warrants a change in regular medication. Predominantly, COPD includes emphysema and chronic bronchitis.

The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to inhaling toxic gases and particles. Although smoking is the main cause of this type of inhalation injury, many other environmental and occupational exposures can also contribute to the pathology of COPD. The immune-inflammatory changes associated with COPD are related to the tissue repair and remodeling process, which increases mucus production and causes emphysema destruction of the lung gas exchange surface. The common form of emphysema in smokers begins in the respiratory bronchioles, near the thickened and narrowed bronchiole, which becomes the main site of COPD obstruction. The mechanism allows the small airways to thicken, which is so close to the lung tissue that it undergoes emphysema destruction.

Although many factors are related to survival in COPD patients, the patient's age and baseline bronchodilator FEV1 are the best predictors of mortality. The presence of mild obstructive airway disease does not indicate a progressive downward course or shorter survival. Mortality in patients with baseline bronchodilator FEV1 greater than or equal to 50% of the predicted value was only slightly higher than in a group of healthy smokers. The age of the patient and the severity of the injury must match closely because younger people and people with fewer injuries can live longer.

Currently, there is no cure for COPD; however, treatment can help slow the disease’s progression and symptoms. Smoking cessation is the best way to reduce COPD progression. Also, regular use of inhaled bronchodilators, either alone or in combination, to prevent and relieve symptoms is the mainstay of COPD management. There are several types of inhalers for COPD, but the main type comprises short-acting bronchodilator inhalers (used when needed to provide immediate symptom relief, especially in mild COPD) and long-acting bronchodilators (used to provide relief for a long duration).

""Chronic Obstructive Pulmonary Disease- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Obstructive Pulmonary Disease pipeline landscape is provided which includes the disease overview and Chronic Obstructive Pulmonary Disease treatment guidelines. The assessment part of the report embraces, in depth Chronic Obstructive Pulmonary Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters

This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Obstructive Pulmonary Disease Emerging Drugs

Benralizumab: AstraZeneca

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG, which gives it a high affinity for the FcγRIIIα receptor in natural killer cells, macrophages, and neutrophils. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation, and migration to the lungs. The drug is currently in Phase III stage of its clinical trial evaluation to treat COPD.

Dupilumab: Sanofi

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis. Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development.

Tezepelumab: Amgen

Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control. Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease.

SNG001: Synairgen

SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD.

GSK3923868: GlaxoSmithKline

GSK3923868, is a PI4kβ inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease.

Further product details are provided in the report……..

Chronic Obstructive Pulmonary Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Obstructive Pulmonary Disease

There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Phases

DelveInsight’s report covers around 70+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Obstructive Pulmonary Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Obstructive Pulmonary Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Obstructive Pulmonary Disease drugs.
 
Chronic Obstructive Pulmonary Disease Report Insights

Chronic Obstructive Pulmonary Disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic Obstructive Pulmonary Disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic Obstructive Pulmonary Disease drugs?

How many Chronic Obstructive Pulmonary Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Obstructive Pulmonary Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Obstructive Pulmonary Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic Obstructive Pulmonary Disease and their status?

What are the key designations that have been granted to the emerging drugs?
 
Key Players

Sanofi

AstraZeneca

Amgen

Synairgen

GlaxoSmithKline

Eisai

Meridigen Biotech

Chiesi

EmeraMed Limited

Verona Pharma

Tetherex Pharmaceuticals

Mereo BioPharma

Key Products

Lemborexant

UMC119-06

CHF5259

Emeramide

Ensifentrine

SNG001

GSK3923868

Benralizumab

Dupilumab

Tezepelumab

SelK2

BCT197